Ovid Therapeutics Inc.
NASDAQ Global SelectTotal Valuation
Ovid Therapeutics Inc. carries a market capitalization of 465.67M, placing it among publicly traded companies globally. Its enterprise value stands at 392.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 465.67M |
| Enterprise Value | 392.49M |
Share Statistics
Ovid Therapeutics Inc. currently has 184.76M shares outstanding.
| Shares Outstanding | 184.76M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 206.64, and the price-to-book ratio stands at 2.37.
| PE Ratio | N/A |
| PS Ratio | 206.64 |
| PB Ratio | 2.37 |
| P/TBV Ratio | 2.37 |
| P/FCF Ratio | -5.97 |
| P/OCF Ratio | -5.97 |
Enterprise Valuation
| EV / Sales | 247.94 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Ovid Therapeutics Inc. maintains a current ratio of 12.39, meaning it holds 12.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.39 |
| Quick Ratio | 11.75 |
| Debt / Equity | 6.06 |
| Debt / EBITDA | -0.22 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -25.97 |
| Return on Assets (ROA) | -22.30 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Ovid Therapeutics Inc.'s stock has gained approximately 78.21429% over the past 52 weeks. The 50-day moving average sits at 2.63, while the 200-day moving average is 2.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | 78.21429% |
| 50-Day Moving Average | 2.63 |
| 200-Day Moving Average | 2.27 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Ovid Therapeutics Inc. generated 1.58M in revenue and converted that into -34.49M in net income, yielding earnings per share of -0.28. EBITDA reached -58.28M, while operating income came in at -58.36M.
| Revenue | 1.58M |
| Gross Profit | N/A |
| Operating Income | -58.36M |
| Pretax Income | -34.49M |
| Net Income | -34.49M |
| EBITDA | -58.28M |
| EBIT | -58.36M |
| Earnings Per Share (EPS) | -0.28 |
Balance Sheet
Ovid Therapeutics Inc. holds 117.22M in cash and equivalents against 12.72M in total debt, resulting in a net debt position of -11.33M. Total book value stands at 209.89M, with working capital of 113.64M providing operational flexibility.
| Cash & Cash Equivalents | 117.22M |
| Total Debt | 12.72M |
| Net Debt | -11.33M |
| Equity (Book Value) | 209.89M |
| Book Value Per Share | 1.14 |
| Working Capital | 113.64M |
Cash Flow
Ovid Therapeutics Inc. produced -54.77M in operating cash flow over the past twelve months.
| Operating Cash Flow | -54.77M |
| Capital Expenditures | N/A |
| Free Cash Flow | -54.77M |
| FCF Per Share | -0.45 |
Margins
Ovid Therapeutics Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -3,686.67 and net profit margin of -2,178.90 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -3,686.67 |
| Pretax Margin | -2,178.90 |
| Profit Margin | -2,178.90 |
| EBITDA Margin | -3,681.36 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -37.38 |
| FCF Yield | -16.74 |
Scores
Ovid Therapeutics Inc. posts an Altman Z-Score of 11.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 11.13 |